Clinical trials: Ambulation Disorder, Neurologic
Multiple Sclerosis
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain…
- Trial name
- NCT00053417
- Testing
- 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Where
- 25 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Acorda Therapeutics
Injuries, Spinal Cord
The WISE Trial - Walking Improvement for SCI With Exoskeleton
A randomized, controlled trial comparing exoskeleton gait training with standard gait training or no gait training in community-dwelling participants with chronic incomplete spinal cord injury
- Trial name
- WISE (NCT02943915)
- Testing
- Ekso GT Rehabilitation Therapy, Body Weight Supported (BWS) Treadmill Training
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ekso Bionics
Spinal Cord Injury
Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury
Powered exoskeletons have emerged recently, promising to offer walking to individuals with severe spinal cord injury who are unable to walk.
- Trial name
- NCT02322125
- Testing
- ReWalk
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Multiple Sclerosis, Walking Impairment
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
- Trial name
- NCT03567057
- Testing
- ADS-5102, 274 mg
- Where
- 92 sites in United States, Canada
- Volunteers
- 424 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Dizziness
"Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?"
Dizziness is a common complaint reported by 30% of people above 65 years of age and by more than 50% of those 90 years of age and older.(1) Age-related decline in vestibular, musculoskeletal, and neurologic performances…
- Trial name
- NCT03403400
- Testing
- VRWP Group, VRW Group
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- AdventHealth
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan…
- Trial name
- NCT00654927
- Testing
- Fampridine-SR b.i.d. (Twice Daily)
- Where
- 22 sites in United States, Canada
- Volunteers
- 177 people
- Sponsor
- Acorda Therapeutics